Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Titel:
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Auteur:
Bennett, Chijioke Woo, Wayne Bloch, Mark Cheung, King Griffin, Paul Mohan, Rahul Deshmukh, Sachin Arya, Mark Cumming, Oscar Neville, A Munro McCallum Pardey, Toni G Plested, Joyce S Cloney-Clark, Shane Zhu, Mingzhu Kalkeri, Raj Patel, Nita Marcheschi, Alex Swan, Jennifer Smith, Gale Cho, Iksung Glenn, Gregory M Walker, Robert Mallory, Raburn M